Top View
- Articles Targeting of Memory T Cells with Alefacept in New-Onset Type 1 Diabetes (T1DAL Study): 12 Month Results of a Randomised
- Biological Therapies in Psoriasis - Revisited
- Drug Class Review Targeted Immune Modulators
- Recent Topics on the Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities
- World Journal of Transplantation
- Alefacept for Severe Alopecia Areata a Randomized, Double-Blind, Placebo-Controlled Study
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
- 2019 Table of Drugs
- Subject Index
- Amevive (Alefacept)
- Alefacept in the Treatment of Recalcitrant Palmoplantar and Erythrodermic Psoriasis
- New Immunosuppression Horizons in Kidney Transplantation
- Alefacept for Psoriasis Michael P
- Alefacept Boosts Response to Methotrexate in Patients with Psoriatic Arthritis
- Alefacept Provides Sustained Clinical and Immunological Effects in New-Onset Type 1 Diabetes Patients
- Impact of Immune-Modulatory Drugs on Tregs Akiko Furukawa, MD, Steven A. Wisel, MD, and Qizhi Tang, Phd Department of Surgery, U
- Systemic Pharmacological Treatments for Chronic Plaque Psoriasis : a Network Meta-Analysis
- Statistical Analysis Plan Version 3
- NON-INTERVENTIONAL (NI) STUDY PROTOCOL PASS Information Title an Observational Cohort Study to Evaluate the Risk of Adverse Preg
- The Long-Term Efficacy and Safety of New Biological Therapies for Psoriasis
- FDA Approved Indications1-3
- Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-Versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network
- Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Patient Management
- Precision Medicine and Not Individualized Therapy Is Required for Successful Novel Drug Development
- WO 2017/117474 Al 6 July 2017 (06.07.2017) W P O P C T
- Beyond Calcineurin Inhibitors: Emerging Agents in Kidney Transplantation
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Drug Class Review Targeted Immune Modulators
- Biologic Immunomodulators June, 2013 by Larry Dent, Pharm.D., BCPS
- Tofacitinib (Xeljanz)
- AMEVIVE (Alefacept)
- CHMP Assessment Report
- Alefacept for Treatment of Moderate to Severe Adult Atopic Dermatitis
- Investigating the Effects of IL-36Γ on Signal Transduction in Human Dermal Fibroblasts
- Guidelines for ATC Classification and DDD Assignment 2021
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- How to Choose My Treatment 1 5 Anna Quinn Hare , Julie Jefferson , and Phoebe Rich
- NOTICE: in July 2004, the Training Program Director's Core
- Guidelines for ATC Classification and DDD Assignment 2013
- COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/PBIRG ANATOMICAL CLASSIFICATION
- A LONG-TERM, OPEN-LABEL EXTENSION STUDY of TOFACITINIB (CP-690,550) for the TREATMENT of PSORIATIC ARTHRITIS Investigational
- Alefacept Treatment in the Setting of Transplantation
- Thalidomide - Wikipedia, the Free Encyclopedia
- Belatacept: the Challenges with Transformational Drugs
- Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
- The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis
- Targeting Treg Signaling for the Treatment of Autoimmune Diseases
- Caresource Pharmacy Policy Statement Marketplace Amevive (Alefacept)
- The Treatment of Moderate-To-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics Danielle Levine, BA,* and Bruce E
- Systemic Combination Treatment for Psoriasis: a Review
- Emerging Drug List MYCOPHENOLATE MOFETIL
- The Journal of Rheumatology Volume 89, No. the Inhibitor of Costimulation of T Cells: Abatacept
- WHO Drug Information Vol 17, No
- Etanercept) B1801396 NON-INTERVENTIONAL STUDY REPORT July 2018 Final Version 3.0 ______
- Review Article
- CER 85: Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis
- Treatment of Psoriatic Arthritis with Biological Agents Arnold Ceponis, MD, and Arthur Kavanaugh, MD